SG10201408162PA - Compositions and methods related to mrna translational enhancer elements - Google Patents

Compositions and methods related to mrna translational enhancer elements

Info

Publication number
SG10201408162PA
SG10201408162PA SG10201408162PA SG10201408162PA SG10201408162PA SG 10201408162P A SG10201408162P A SG 10201408162PA SG 10201408162P A SG10201408162P A SG 10201408162PA SG 10201408162P A SG10201408162P A SG 10201408162PA SG 10201408162P A SG10201408162P A SG 10201408162PA
Authority
SG
Singapore
Prior art keywords
compositions
enhancer elements
methods related
translational enhancer
mrna translational
Prior art date
Application number
SG10201408162PA
Inventor
Vincent P Mauro
Gerald M Edelman
Wei Zhou
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG10201408162PA publication Critical patent/SG10201408162PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201408162PA 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements SG10201408162PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US744007P 2007-12-11 2007-12-11

Publications (1)

Publication Number Publication Date
SG10201408162PA true SG10201408162PA (en) 2015-01-29

Family

ID=40386467

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201408165WA SG10201408165WA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG2013017025A SG188866A1 (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG10201408162PA SG10201408162PA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG10201408164XA SG10201408164XA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201408165WA SG10201408165WA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements
SG2013017025A SG188866A1 (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201408164XA SG10201408164XA (en) 2007-12-11 2008-12-11 Compositions and methods related to mrna translational enhancer elements

Country Status (8)

Country Link
US (2) US8785611B2 (en)
EP (5) EP2610340B1 (en)
JP (3) JP5474816B2 (en)
CN (2) CN101939428B (en)
AU (1) AU2008335723C1 (en)
CA (2) CA2904904A1 (en)
SG (4) SG10201408165WA (en)
WO (1) WO2009075886A1 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009644A2 (en) * 2010-07-16 2012-01-19 Arizona Board Of Regents Methods to identify synthetic and natural rna elements that enhance protein translation
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (en) 2010-10-01 2022-09-28 Modernatx Inc Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (en) 2011-10-03 2022-03-31 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104114572A (en) 2011-12-16 2014-10-22 现代治疗公司 Modified nucleoside, nucleotide, and nucleic acid compositions
JP2015518705A (en) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of biologics and proteins associated with human diseases
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
JP2016504050A (en) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Signal sensor polynucleotide for modification of cell phenotype
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (en) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor.
EP3336192B1 (en) * 2013-11-12 2021-12-08 Vrije Universiteit Brussel Rna transcription vector and uses thereof
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
PL3350333T3 (en) 2015-09-17 2022-03-07 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
SI3350157T1 (en) 2015-09-17 2022-04-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US20190218546A1 (en) 2015-10-16 2019-07-18 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
EP3362460A1 (en) 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
JP7114465B2 (en) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of drugs
PT3394093T (en) 2015-12-23 2022-05-30 Modernatx Inc Methods of using ox40 ligand encoding polynucleotides
EP3400023A1 (en) 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
CA3024624A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
EP3458107B1 (en) 2016-05-18 2024-03-13 ModernaTX, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
MY201498A (en) 2016-05-18 2024-02-27 Modernatx Inc Polynucleotides encoding citrin for the treatment of citrullinemia type 2
MX2018013509A (en) 2016-05-18 2019-03-28 Modernatx Inc Polynucleotides encoding interleukin-12 (il12) and uses thereof.
EP3458105B1 (en) 2016-05-18 2024-01-17 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
KR102482867B1 (en) 2016-05-18 2023-01-02 모더나티엑스, 인크. Combinations of mRNAs encoding immune modulatory polypeptides and uses thereof
WO2017201328A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
DK3596041T3 (en) 2017-03-15 2023-01-23 Modernatx Inc COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
ES2952779T3 (en) 2017-05-18 2023-11-06 Modernatx Inc Modified messenger RNA comprising functional RNA elements
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods of preparing modified rna
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
EP3773745A1 (en) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger rna comprising functional rna elements
CA3113436A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
US20210378980A1 (en) 2018-09-20 2021-12-09 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020160397A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
BR112021014909A2 (en) 2019-01-31 2021-11-23 Modernatx Inc Vortex stirrers and associated methods, systems and apparatus thereof
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
EP3987027A1 (en) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonuclease-resistant messenger rna and uses thereof
JP2023511633A (en) 2020-01-28 2023-03-20 モデルナティエックス インコーポレイテッド coronavirus RNA vaccine
CA3170150A1 (en) 2020-02-07 2021-08-12 Modernatx, Inc. Sars-cov-2 mrna domain vaccines
JP2023529522A (en) 2020-04-09 2023-07-11 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド Lipid nanoparticle composition
TW202204622A (en) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 Nucleic acid vaccines for coronavirus
WO2021222304A1 (en) 2020-04-27 2021-11-04 Modernatx, Inc. Sars-cov-2 rna vaccines
WO2021159130A2 (en) 2020-05-15 2021-08-12 Modernatx, Inc. Coronavirus rna vaccines and methods of use
AU2021301922A1 (en) 2020-06-30 2023-02-02 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
EP4185274A1 (en) 2020-07-24 2023-05-31 Strand Therapeutics Inc. Lipidnanoparticle comprising modified nucleotides
TW202214566A (en) 2020-08-20 2022-04-16 大陸商蘇州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
US20230355743A1 (en) 2020-09-25 2023-11-09 Modernatx, Inc. Multi-proline-substituted coronavirus spike protein vaccines
JP2024503000A (en) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド Expression constructs and their use
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022152141A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Polymer conjugated lipid compounds and lipid nanoparticle compositions
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
AU2022207495A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
AU2022208057A1 (en) 2021-01-15 2023-08-03 Modernatx, Inc. Variant strain-based coronavirus vaccines
JP2024511346A (en) 2021-03-15 2024-03-13 モデルナティエックス インコーポレイテッド Therapeutic use of SARS-COV-2 mRNA domain vaccines
JP2024512780A (en) 2021-04-01 2024-03-19 モデルナティエックス インコーポレイテッド Method for identification and ratio determination of RNA species in multivalent RNA compositions
AU2022258335A1 (en) 2021-04-13 2023-11-23 Modernatx, Inc. Respiratory virus combination vaccines
AU2022258463A1 (en) 2021-04-14 2023-11-23 Modernatx, Inc. Influenza-coronavirus combination vaccines
WO2022245888A1 (en) 2021-05-19 2022-11-24 Modernatx, Inc. Seasonal flu rna vaccines and methods of use
CN116472275A (en) 2021-05-24 2023-07-21 苏州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
US20240218353A1 (en) 2021-06-17 2024-07-04 Modernatx, Inc. Alternative rna purification strategies
TW202321446A (en) 2021-08-13 2023-06-01 美商現代公司 Multicolumn chromatography mrna purification
AR127312A1 (en) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
CN116064598B (en) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 Nucleic acid vaccine for coronavirus
EP4204391A1 (en) 2021-10-08 2023-07-05 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
KR20240090727A (en) 2021-10-22 2024-06-21 세일 바이오메디슨스, 인크. mRNA vaccine composition
WO2023076658A1 (en) 2021-11-01 2023-05-04 Modernatx, Inc. Mass spectrometry of mrna
WO2023081311A1 (en) 2021-11-05 2023-05-11 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023092069A1 (en) 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
AU2022398450A1 (en) 2021-11-23 2024-06-06 Sail Biomedicines, Inc. A bacteria-derived lipid composition and use thereof
WO2023107999A2 (en) 2021-12-08 2023-06-15 Modernatx, Inc. Herpes simplex virus mrna vaccines
WO2023122080A1 (en) 2021-12-20 2023-06-29 Senda Biosciences, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
CN116332830A (en) 2021-12-23 2023-06-27 苏州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
WO2023132885A1 (en) 2022-01-04 2023-07-13 Modernatx, Inc. Methods of purifying dna for gene synthesis
WO2023137149A1 (en) 2022-01-14 2023-07-20 Modernatx, Inc. In vitro transcription dna purification and recycling
WO2023150256A1 (en) 2022-02-03 2023-08-10 Modernatx, Inc. Continuous precipitation for mrna purification
WO2023196914A1 (en) 2022-04-08 2023-10-12 Modernatx, Inc. Influenza nucleic acid compositions and uses thereof
WO2023201296A1 (en) 2022-04-15 2023-10-19 Modernatx, Inc. Ribosomal engagement potency assay
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023230481A1 (en) 2022-05-24 2023-11-30 Modernatx, Inc. Orthopoxvirus vaccines
WO2024010993A1 (en) 2022-07-06 2024-01-11 Modernatx, Inc. Primer design for cell-free dna production
WO2024015890A1 (en) 2022-07-13 2024-01-18 Modernatx, Inc. Norovirus mrna vaccines
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024050483A1 (en) 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024097874A1 (en) 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
WO2024102434A1 (en) 2022-11-10 2024-05-16 Senda Biosciences, Inc. Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US6116184A (en) 1996-05-21 2000-09-12 Symetrix Corporation Method and apparatus for misted liquid source deposition of thin film with reduced mist particle size
WO1998037189A1 (en) * 1997-02-25 1998-08-27 Qbi Enterprises Ltd. Ires sequences with high translational efficiency and expression vectors containing the sequence
JP2001521759A (en) 1997-11-12 2001-11-13 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド Translational enhancer element of human amyloid precursor protein gene
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
CA2357709A1 (en) * 1999-01-26 2000-08-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Internal ribosome entry site (ires), vector containing same and uses thereof
US7183395B2 (en) * 2000-01-28 2007-02-27 The Scripps Research Institute Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
WO2001071036A2 (en) * 2000-03-17 2001-09-27 Gene Logic, Inc. Methods of preparing amplified nucleic acid molecules
EP1315816B1 (en) * 2000-09-08 2010-12-29 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
WO2007025008A2 (en) 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems

Also Published As

Publication number Publication date
WO2009075886A1 (en) 2009-06-18
CA2708766C (en) 2016-02-02
EP2584038B1 (en) 2014-06-25
SG10201408164XA (en) 2015-01-29
AU2008335723A1 (en) 2009-06-18
CN101939428A (en) 2011-01-05
CA2904904A1 (en) 2009-06-18
EP2610340B1 (en) 2014-10-01
EP2527439B1 (en) 2014-03-26
CA2708766A1 (en) 2009-06-18
EP2610340A1 (en) 2013-07-03
EP2610341A1 (en) 2013-07-03
SG188866A1 (en) 2013-04-30
EP2584038A1 (en) 2013-04-24
SG10201408165WA (en) 2015-01-29
EP2231859A1 (en) 2010-09-29
US20130177581A1 (en) 2013-07-11
JP2016104027A (en) 2016-06-09
JP5873511B2 (en) 2016-03-01
WO2009075886A8 (en) 2010-11-11
AU2008335723B2 (en) 2012-12-13
EP2527439A3 (en) 2012-12-05
EP2231859B1 (en) 2013-01-23
CN101939428B (en) 2014-05-07
JP5474816B2 (en) 2014-04-16
JP2011505831A (en) 2011-03-03
US8785611B2 (en) 2014-07-22
JP2014113163A (en) 2014-06-26
EP2610341B1 (en) 2014-09-17
AU2008335723C1 (en) 2013-05-30
EP2527439A2 (en) 2012-11-28
US20090226470A1 (en) 2009-09-10
CN103911378A (en) 2014-07-09

Similar Documents

Publication Publication Date Title
SG10201408162PA (en) Compositions and methods related to mrna translational enhancer elements
ZA201001300B (en) Antigen-asjuvant compositions and methods
IL210153A0 (en) Nutrigenomics methods and compositions
HK1159428A1 (en) Compositions comprising sweetness enhancers and methods of making them
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0819530D0 (en) Methods and compositions
EP2315600A4 (en) Compositions and methods related to sirt1 function
ZA200905508B (en) Compositions and methods to prevent cancer with cupredoxins
IL210559A0 (en) Novel compositions and methods
EP2370815A4 (en) Anti-inflammatory compositions and methods
IL208483A (en) Limk2 inhibitors and compositions comprising them
IL210588A0 (en) Novel compositions and methods
GB0721291D0 (en) Methods and compositions
EP2361087A4 (en) Anti-inflammatory compounds and compositions thereof
GB0817585D0 (en) Novel compositions and methods
GB0719526D0 (en) Compositions and methods
IL213636A0 (en) Compositions and methods to prevent cancer with cupredoxins
IL213657A0 (en) Compositions and methods to prevent cancer with cupredoxins
PT2320888E (en) Laidlomycin compositions and methods
GB0811250D0 (en) Methods and compositions
ZA201100008B (en) Anti-tumour compositions and methods
GB0724549D0 (en) Compositions and methods
GB0723775D0 (en) Methods and compositions
GB0717683D0 (en) Compositions and methods
GB0803464D0 (en) Methods and compositions